Contineum Therapeutics (CTNM) Revenue (2023)
Contineum Therapeutics (CTNM) posted quarterly Revenue of $50.0 million for Q2 2023.
Contineum Therapeutics (CTNM) Revenue (2023) Analysis & Trends
Contineum Therapeutics' Revenue history runs 1 years deep, the most recent figure standing at $50.0 million for Q2 2023.
- In Q2 2023, Revenue changed N/A year-over-year to $50.0 million; the TTM figure through Jun 2024 stood at $50.0 million (changed N/A YoY), while the FY2023 annual figure was $50.0 million, changed N/A from the prior year.
- Revenue for Q2 2023 stood at $50.0 million.
- The five-year high for Revenue was $50.0 million in Q2 2023, with the low at $50.0 million in Q2 2023.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Revenue (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 3.33 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 4.29 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 1.56 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 1.71 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 3,001.92 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 674.14 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.29 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 425.49 Mn |
| 10 | Contineum Therapeutics | 533.73 Mn | 533.73 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2023 | 50.00 Mn |